Literature DB >> 17630254

Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional blunting.

Julie D Henry1, Melissa J Green, Amber de Lucia, Corinne Restuccia, Skye McDonald, Maryanne O'Donnell.   

Abstract

A prominent emotional disturbance in schizophrenia is clinically evident in blunted affect, often observed as reduced emotional expressivity alongside the individual's report of normal or heightened emotional experience. It has been suggested that this disjunction between the experience and expression of emotion may reflect problems with the regulation of emotional expression. The present study thus set out to examine the capacity to engage in particular emotion regulatory strategies, and specifically, the ability to amplify the emotional expression of an experienced emotion ('amplification') or suppress the emotional expression of an experienced emotion ('suppression') whilst watching film clips selected to elicit amusement. Twenty nine participants with schizophrenia and 30 demographically matched non-clinical controls were asked to watch three different amusing film clips, whilst engaging in different regulatory strategies. The results indicate that participants with schizophrenia have difficulties with the amplification (but not suppression) of emotion expressive behavior. These difficulties are significantly correlated with total negative symptoms experienced, particularly emotional blunting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630254     DOI: 10.1016/j.schres.2007.06.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  34 in total

1.  Emotion Regulation Predicts Everyday Emotion Experience and Social Function in Schizophrenia.

Authors:  Erin K Moran; Adam J Culbreth; Deanna M Barch
Journal:  Clin Psychol Sci       Date:  2017-11-16

Review 2.  Reconsidering Emotion Dysregulation.

Authors:  Alessandra D'Agostino; Serena Covanti; Mario Rossi Monti; Vladan Starcevic
Journal:  Psychiatr Q       Date:  2017-12

3.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

Review 4.  Exploring the impact of parental psychopathology and emotion regulation on evidence-based parenting interventions: a transdiagnostic approach to improving treatment effectiveness.

Authors:  Ashley C Maliken; Lynn Fainsilber Katz
Journal:  Clin Child Fam Psychol Rev       Date:  2013-06

5.  Can I trust you? Negative affective priming influences social judgments in schizophrenia.

Authors:  Christine I Hooker; Laura M Tully; Sara C Verosky; Melissa Fisher; Christine Holland; Sophia Vinogradov
Journal:  J Abnorm Psychol       Date:  2011-02

6.  Emotion responsivity, social cognition, and functional outcome in schizophrenia.

Authors:  Jennifer R Mathews; Deanna M Barch
Journal:  J Abnorm Psychol       Date:  2010-02

7.  Emotion regulation abnormalities in schizophrenia: Directed attention strategies fail to decrease the neurophysiological response to unpleasant stimuli.

Authors:  Gregory P Strauss; Emily S Kappenman; Adam J Culbreth; Lauren T Catalano; Kathryn L Ossenfort; Bern G Lee; James M Gold
Journal:  J Abnorm Psychol       Date:  2014-12-08

8.  Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia.

Authors:  Ivy F Tso; Tyler B Grove; Stephan F Taylor
Journal:  Schizophr Res       Date:  2010-01-03       Impact factor: 4.939

Review 9.  Emotional response deficits in schizophrenia: insights from affective science.

Authors:  Ann M Kring; Erin K Moran
Journal:  Schizophr Bull       Date:  2008-06-25       Impact factor: 9.306

10.  Anhedonia and ambivalence in schizophrenic patients with fronto-cerebellar metabolic abnormalities: a fluoro-d-glucose positron emission tomography study.

Authors:  Kyung-Min Park; Jae-Jin Kim; Jeong Ho Seok; Ji Won Chun; Hae-Jeong Park; Jong Doo Lee
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.